Repeated radioimmunotherapy with 131I-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma-Reference-Cited by-同舟云学术

Repeated radioimmunotherapy with 131I-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma

Published:2013-01-31 Issue:4 Volume:71 Page:945-953
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Kang Hye Jin,Lee Seung-Sook,Byun Byung Hyun,Kim Kyeong Min,Lim Ilhan,Choi Chang Woon,Suh Cheolwon,Kim Won Seog,Nam Seung-Hyun,Lee Soon Il,Eom Hyeon Seok,Shin Dong-Yeop,Lim Sang Moo

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-013-2087-z.pdf

Reference16 articles.

1. Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L, Lister TA, Stagg RJ, Tidmarsh GF, Kroll S, Wahl RL, Knox SJ, Vose JM (2001) Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol 19(19):3918–3928

2. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-Lopez AJ, Multani P, White CA (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 20(10):2453–2463

3. Leahy MF, Seymour JF, Hicks RJ, Turner JH (2006) Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin’s lymphoma. J Clin Oncol 24(27):4418–4425

4. Kang HJ, Lee SS, Kim KM, Choi TH, Cheon GJ, Kim WS, Suh C, Yang SH, Lim SM (2011) Radioimmunotherapy with (131)I-rituximab for patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma (NHL). Asia Pac J Clin Oncol 7(2):136–145

5. Stabin MG (1996) MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 37(3):538–546

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ロジウムを用いた新中性子捕捉療法の試み—ベータ線に基づく抗腫瘍治療法—;RADIOISOTOPES;2024-03-15

2. Radioimmunotherapy with ¹³¹I‐rituximab for patients with relapsed or refractory follicular or mantle cell lymphoma;Asia-Pacific Journal of Clinical Oncology;2023-03-13

3. Current and upcoming radionuclide therapies in the direction of precision oncology: A narrative review;European Journal of Radiology Open;2023

4. A Phase II Study of ¹³¹I-rituximab for Patients With Relapsed or Refractory Marginal Zone Lymphoma;Clinical Medicine Insights: Oncology;2023-01

5. Radioiodination of Modified Porous Silica Nanoparticles as a Potential Candidate of Iodine-131 Drugs Vehicle;ACS Omega;2022-04-18